key: cord-0913892-1bwwcrbo
authors: Fowotade, A.; Bamidele, F.; Egbetola, B.; Adefuye, B. O.; Fagbamigbe, A. F.; Adeagbo, B. A.; Olagunoye, A.; Ojo, T. O.; Adebiyi, A. O.; Olagunju, O. I.; Ladipo, O. T.; Akinloye, A.; Onayade, A.; Bolaji, O. O.; Happi, C.; Rannard, S.; Owen, A.; Olagunju, A.
title: Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19
date: 2022-02-04
journal: nan
DOI: 10.1101/2022.02.03.22270152
sha: cb527cff9264dfb2e6f69274eff0215ec79636e4
doc_id: 913892
cord_uid: 1bwwcrbo

Background: Finding effective therapeutics for COVID-19 continues to be an urgent need, especially considering use context limitations and cost of currently approved agents. The NACOVID trial investigated the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, used in combination for COVID-19. Methods: In this pilot, randomized, open label trial conducted in Nigeria, patients diagnosed with mild to moderate COVID-19 were randomly assigned to receive standard of care (SoC) or SoC plus 14-day course of nitazoxanide (1000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od) and followed through day 28. Study endpoints included time to clinical improvement, SARS-CoV-2 viral load change, and time to complete symptoms resolution. Safety and pharmacokinetics of nitazoxanide active metabolite, tizoxanide, were also evaluated. This trial was registered with ClinicalTrials.gov (NCT04459286). Findings: There was no difference in time to clinical improvement between the SoC (n = 26) and SoC plus intervention arms (n = 31; Cox proportional hazards regression analysis adjusted hazard ratio, aHR = 0.898, 95% CI: 0.492-1.638, p = 0.725). No difference was observed in the pattern of saliva SARS-CoV-2 viral load changes from days 2 to 28 in the 35% of patients with detectable virus at baseline (20/57) between the two arms (aHR = 0.948, 95% CI: 0.341-2.636, p = 0.919). There was no significant difference in time from enrolment to complete symptoms resolution (aHR = 0.535, 95% CI: 0.251 -1.140, p = 0.105). Atazanavir/ritonavir increased tizoxanide plasma exposure by 68% and median trough plasma concentration was 1546 ng/ml (95% CI: 797-2557), above its putative EC90 in 54% of patients. Tizoxanide was not detectable in saliva. Interpretation: These findings should be interpreted in the context of incomplete enrolment (64%) and the limited number of patients with detectable SARS-CoV-2 in saliva at baseline in this trial.

Background Finding effective therapeutics for COVID-19 continues to be an urgent need, especially considering use context limitations and high cost of currently approved agents. The NACOVID trial investigated the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, used in combination for COVID-19.

In this pilot, randomized, open-label trial conducted in Nigeria, patients diagnosed with mild to moderate COVID-19 were randomly assigned to receive standard of care (SoC) or SoC plus a 14-day course of nitazoxanide (1000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od) and followed through day 28. Study endpoints included time to clinical improvement, SARS-CoV-2 viral load change, and time to complete symptom resolution. Safety and pharmacokinetics of nitazoxanide active metabolite, tizoxanide, were also evaluated. This trial was registered with ClinicalTrials.gov (NCT04459286).

Findings There was no difference in time to clinical improvement between the SoC (n = 26) and SoC plus intervention arms (n = 31; Cox proportional hazards regression analysis adjusted hazard ratio, aHR = 0.898, 95% CI: 0.492-1.638, p = 0.725). No difference was observed in the pattern of saliva SARS-CoV-2 viral load changes from days 2 to 28 in the 35% of patients with detectable virus at baseline (20/57) between the two arms (aHR = 0.948, 95% CI: 0.341-2.636, p = 0.919). There was no significant difference in time from enrolment to complete symptom resolution (aHR = 0.535, 95% CI: 0.251 -1.140, p = 0.105). Atazanavir/ritonavir increased tizoxanide plasma exposure by 68% and median trough plasma concentration was 1546 ng/ml (95% CI: 797-2557), above its putative EC90 in 54% of patients. Tizoxanide was not detectable in saliva.

With over 350 million cases and more than 5.6 million deaths at the end of January 2022, 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint 19 ) is by far the most devastating pandemic known to anyone alive. 3 More than 2900 vaccine or therapeutic clinical trials have been registered and hundreds are either completed or ongoing. 4 Remdesivir, an intravenous nucleotide prodrug originally developed for Ebola virus disease, 5 was the first drug approved by the FDA in October 2020. Emergency use authorisations were issued in December 2021 for paxlovid 6 and molnupiravir, 7 both orally administered antiviral agents. Though non-pharmaceutical interventions have helped to break the chain of transmission and global deployment of effective vaccines has reduced disease severity, there is an urgent need for additional effective therapeutics for treatment and/or prevention of COVID-19.

In a report of in vitro studies on the anti-coronavirus activity of 727 compounds in the National Institutes of Health Clinical Collection small molecule library, 84 drugs with significant anti-coronavirus activity were identified, including 51 entry blockers and 19 inhibitors of viral replication in cell culture using a luciferase reporter-expressing recombinant murine coronavirus. 8 Nitazoxanide was among the top three inhibitors, resulting in a reduction of 6 log10 in virus titre with an IC50 of 1.0 µM. The major circulating metabolite of nitazoxanide is tizoxanide and recent work by the NIH National Centre for Advancing Translational Sciences confirmed its in vitro activity against SARS-CoV-2 in Vero E6 host cells via suppression of viral cytopathic effect. 9 We previously identified nitazoxanide among the only 14 drugs able to achieve plasma and lung concentration above the EC90 for SARS-CoV-2 at approved doses out of 56 drugs with reported in vitro activity. 10 In a follow-up study, we explored optimal nitazoxanide dosing schedules for maintaining effective tizoxanide plasma and lung concentrations. 11 The susceptibility of 210 seasonal influenza viruses to nitazoxanide and its metabolite tizoxanide has been reported 12 and nitazoxanide reduced symptom duration in acute uncomplicated influenza 13 . SARS-CoV-2 shares almost 80% of the genome with SARS-CoV 14 and almost all encoded proteins of SARS-CoV-2 are homologous to SARS-CoV proteins. 15 Hence, nitazoxanide and its metabolite tizoxanide with demonstrated in vitro activity against SARS-CoV are considered potential candidates for COVID-19.

The HIV protease inhibitor, atazanavir (boosted with ritonavir), has been shown to inhibit the major protease enzyme required for viral polyprotein processing during coronavirus replication. 16, 17 It also . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint blocks pro-inflammatory cytokine production. 16 Additionally, tizoxanide is inactivated by glucuronidation and atazanavir is a well-known inhibitor. 18 Hence, atazanavir is expected to enhance tizoxanide exposure when used in combination with nitazoxanide. Drug repurposing often requires consideration of target concentrations and dosing regimens that may not be identical to previously defined labels where optimization was conducted for a different disease. Importantly, widespread deployment of antiviral monotherapies for pulmonary viruses (e.g. influenza virus) often leads to the emergence of resistance and we previously called for caution in this regard. 19 Therefore, to take advantage of the anticipated favourable drug-drug interaction, a combination of nitazoxanide and atazanavir/ritonavir was selected for this trial.

The nitazoxanide plus atazanavir/ritonavir for COVID-19 (NACOVID) trial is a pilot open-label randomised phase 2, multicentre, two-arm controlled trial conducted in Nigeria. Patients who recently tested positive for SARS-CoV-2 by means of reverse transcription-polymerase chain reaction (RT-PCR) assay and were symptomatic were eligible. Patients were considered to have a mild disease if they were ambulatory, need little or no assistance. Those with moderate disease were non-ambulatory but had no need for oxygen therapy, or required oxygen by mask or nasal prongs. Severely ill patients that is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. 

Patients were randomly assigned in a 1:1 ratio to receive either standard of care alone or standard of care combined with 1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily. Randomisation was implemented using a Research Electronic Data Capture (REDCap) 21 module that centrally stratified patients by study site, diagnosis CT value, gender, existence of comorbidities and disease severity at enrolment. Standard of care was according to the national interim guidelines for clinical management of COVID-19, including antipyretics for fever, cough medicine, antimalaria in cases with malaria co-infection, multivitamins and mineral supplement, and ongoing treatment of pre-existing comorbidities. Participation in other interventional studies or offlabel use of other medications intended as specific treatment for COVID-19 outside the standard of care was not allowed throughout the 28-day study period.

On study day 0 (baseline), patients provided informed consent and were assessed for eligibility. Site clinical investigators documented demographic and anthropometric information, recent and current medical history including confirmation of COVID-19 diagnosis and disease severity, pregnancy test for reproductive age women, concomitant medications, physical examination, vital signs, and safety . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint blood for haematology and biochemistry. Those who met the eligibility criteria were enrolled and randomised to either continue the standard of care alone (started before study entry in all participants) or trial intervention in addition. The intervention consisted of 1000 mg nitazoxanide twice daily and 300/100 mg atazanavir/ritonavir administered orally once daily in the night, both administered orally after a meal and directly observed by study staff on days 1 to 14.

Daily assessment of vitals including SpO2, symptom monitoring using the Flu-PRO questionnaire and clinical improvement as well as adverse event monitoring was conducted by designated staff at each study site for all patients on days 1 to day 14, and on days 21 and 28. Saliva for SARS-CoV-2 viral load was collected on days 0, 2, 4, 6, 7, 14, and 28. Saliva and dried blood spots for quantification of tizoxanide, the active metabolite of nitazoxanide, were collected on days 2, 4, 6, 7, and 14 about the same time as viral load samples. Patients who were discharged from the isolation and treatment is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint with the following categories: 0, uninfected with no viral RNA detected; 1, asymptomatic with viral RNA detected; 2, symptomatic but independent; 3, symptomatic and in need of assistance; 4, hospitalized but not requiring oxygen therapy; 5, hospitalised and requires oxygen by mask or nasal prongs; 6, hospitalized and requires oxygen by NIV or high flow; 7, intubated and on mechanical ventilation with PaO2/FiO2 ≥150 or SpO2/FiO2 ≥200; 8, on mechanical ventilation with PaO2/FiO2 ˂150 (SpO2/FiO2 ˂200) or vasopressors; 9, on mechanical ventilation with PaO2/FiO2 ˂150 and vasopressors, dialysis, or extracorporeal membrane oxygenation; 10, dead. Secondary outcomes included time to symptom resolution, clinical status on days 7 and 14 based on the 10-category ordinal scale, day 28 mortality, time from treatment initiation to death and proportion of participants with viral RNA detection over time.

For the assessment of pharmacokinetic endpoints, sparse dried blood spots samples were collected on Whatman 903 protein saver cards (VWR International Ltd, Leicestershire, UK) at steady state to determine the mid-dose concentration of tizoxanide, the active metabolite of nitazoxanide. Saliva samples for tizoxanide quantification were collected at the same time as saliva samples for SARS-CoV-2 viral load on days 2, 4, 6, 7 and 14. The drug-drug interaction potential of nitazoxanide and atazanavir/ritonavir was investigated in a separate healthy volunteer, two-period cross-over study. In brief, drug-free healthy volunteers (18-35 years old, male and female) were recruited. Each volunteer received 1000 mg nitazoxanide 12 hourly after a standard meal for 5 days in the first period, followed by a 21-day washout period. In the second stage, they received 1000 mg nitazoxanide 12 hourly combined with 300/100 mg atazanavir/ritonavir once daily for 5 days. Plasma samples were collected at 0.25, 0.5, 1, 2, 4, 6, and 12 hours after dose on days 1 and 5 during both stages. Tizoxanide quantification was by validated LC-MS/MS methods on TSQ Vantage (Thermo Electron Corporation, Hemel Hempstead, Hertfordshire, UK) with 50 ng/ml lowest limit of quantification. Data from the first seven participants who completed day 1 of both periods are included in this paper to show the outcome of single-dose interaction. The full study, including an embedded clinical cross validation of the plasma and dried blood spot bioanalytical methods, will be published separately. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

A sample size of 98 was estimated to provide more than 80% power to show or exclude 60% improvement in time to SARS-CoV-2 RT-PCR negativity in the intervention group compared with the control group at a two-sided type 1 error rate of 5%. Between-group (SOC vs Intervention) comparisons of demographic, anthropometric, clinical and laboratory data of the participants were conducted using independent sample t-test and Chi-square test of association for continuous and 

There was no external funding source for this study.

The first patient was enrolled on November 25, 2020 and the last patient was enrolled on April 20, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. 

The mean age of patients in the standard of care alone arm was 40 years (standard deviation: 18) and 37 years (13) in the standard of care plus intervention arm. Most participants were male with mean body weights of 67 kg and 70 kg, respectively. In both arms, about 50% of patients were enrolled within 1-4 days of receiving their diagnosis. All baseline characteristics were similar between both groups (Table 1) .

At the time of enrolment, 19 of the 26 patients randomised to the standard of care alone arm were graded 5 (required oxygen by mask or nasal prongs), 3 were graded 4 (non-ambulatory but did not require oxygen therapy), 1 was graded 2 (symptomatic but ambulatory and independent), and 3 were graded 1 (asymptomatic and ambulatory). Of the 31 patients randomised to the standard of care plus intervention, 23 were graded 5, 3 were graded 4, 2 were graded 3 (ambulatory, but symptomatic and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint need assistance), 1 was graded 2, and 2 were graded 1. The time to achieve protocol-defined clinical improvement (a drop of 2 levels on the 1-10 ordinal scale) in the entire cohort was 7 days and no difference was observed between the two arms (7 days in the standard of care arm alone versus 8 days in the standard of care plus intervention arm). The hazard ratio (HR) was 1.027 (95% CI: 0.592-1.783), p = 0.924 and no difference was observed after adjusting for potential co-founders in Cox proportional hazards regression analysis, including randomisation stratification variables (aHR = 0.898, 95% CI: 0.492-1.638, p = 0.725; Figure 2 ). In a separate analysis, we further explored time to clinical improvement in various subgroups using logrank tests but found no significant differences between both arms (Table S1 ).

SARS-CoV-2 was detectable in saliva samples collected at enrolment only in 35% (20/57) of patients with a mean of 5.05 log10 copies/ml in SoC alone arm, and 5.17 log10 copies/ml in SoC plus intervention arm. In a very limited analysis of this outcome using days 2, 4, 6, 7, 14 and 28 follow up saliva viral load data from these patients, there was no trend towards a difference in the pattern of viral load changes between the two arms, Welch's t-test p value = 0.758 for comparison of means over the follow-up period (Figure 3 ). The aHR was 0.948 (0.341-2.636) with a p value of 0.919.

The median time from enrolment to complete symptom resolution was 8 days in the entire cohort, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint of median time to complete symptom resolution in various subgroups using logrank tests showed no trend towards any benefit in combining the intervention with the standard of care (Table S2) .

The DSMB at their meeting of 14 November 2021 recommended terminating the trial as no further opportunities existed to recruit additional patients and accrued data did not indicate any trend of benefit in adding the intervention to the standard of care.

Nitazoxanide (1000 mg b.i.d.) combined with the usual dose of atazanavir/ritonavir (300/100 mg od) was well tolerated in this cohort. Laboratory values of haematology and blood chemistry parameters on days 0, 7, and 14 were within normal ranges (Table S3) 

We compared concentration-time data from day 1 of both periods of the drug-drug interaction study from seven healthy volunteers: 4 females and 3 males aged 24.4 years (4.8) with 56.6 kg (7.5) body weight. Co-administration of nitazoxanide (NTZ) with atazanavir/ritonavir (ATZ/r) increased plasma tizoxanide AUC0-12 by from 37.6 µg.h/ml to 63.3 µg.h/ml (68.3%) and its Cmax from 7630 ng/ml to 8730 ng/ml (14.4%) ( Figure 5A ). A total of 110 concentration-time data were available from the 31 patients in the standard of care plus intervention arm. Median tizoxanide trough plasma concentration was 1546 ng/ml (95% CI: 797-2557), above its putative EC90 in 54% of patients 23 ( Figure 5B ). An EC90 of 1430 ng/ml was reported for nitazoxanide in reversing SARS-CoV-2 induced cytopathic effect in Vero E6 host cells, and tizoxanide is expected to have a similar in vitro potency. 9 Tizoxanide was undetectable in saliva samples collected in the drug-drug interaction study and from patients.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint

In this pilot randomised open-label trial, patients who received a 14-day course of nitazoxanide (1000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od) in addition to standard of care initiated within a few days of COVID-19 diagnosis did not experience a better outcome (clinical improvement, viral clearance, and symptom resolution) compared with those who received standard of care alone.

Crucially, tizoxanide plasma exposure was significantly enhanced when combined with atazanavir/ritonavir as expected, possibly via inhibition of its inactivation through glucuronidation. 18 Though concentration in patients at 12 hours after dose was lower than in healthy volunteers, an observation that may be due to the influence of certain components of standard of care, it was above the putative tizoxanide plasma EC90 in more than 50% of patients. This is similar to the achievement of plasma concentration above the EC90 in 51% of virtual subjects given 1000 mg b.i.d. nitazoxanide with food. 11 However, tizoxanide was undetectable in saliva samples collected from participants in the drug-drug interaction study and in patients throughout the follow-up period. Tizoxanide is highly bound to plasma proteins (over 99.9%) and we previously highlighted the critical importance of this parameter for in vitro to in vivo extrapolation. 24 Our predictions of tizoxanide distribution to human lung 10,11 based on physicochemical properties, in vitro drug binding information, and tissue-specific data did not accurately recapitulate in vivo observation.

Confirmation of in vitro activity of nitazoxanide against SARS-CoV-2 prompted efforts to investigate its efficacy as a repurposed drug for COVID-19. Several ongoing, completed, or terminated clinical trials include nitazoxanide as monotherapy or as part of a combination strategy. A preprint of interim analysis from a study by Silva et al (clinicaltrials.gov identifier: NCT04463264; n = 45) showed no difference in the achievement of PCR negativity by day 7 (62.5% of patients in the 500 mg q.i.d.

nitazoxanide arm versus 53.9% in the placebo arm, p = 0.620), though more of those treated with nitazoxanide had viral load reduction of 35% or more from baseline up to day 7 (47.8% versus 15.4%; p = 0.037). 25 In a preprint of results from the Vanguard study (NCT04486313, n = 379) that enrolled outpatients with mild or moderate COVID-19 within 72 hours of symptom onset, 600 mg b.i.d. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint 0.5%) compared with placebo (7/195, 3.6%; p = 0.07). There was no overall difference in time to sustained clinical recovery and a non-significant trend towards a quicker time to symptom resolution and return to usual health was observed. 26 The Elalfy et al study (NCT04392427, n = 113) reported a cumulative day-15 SARS-CoV-2 clearance rate of 88.7% in patients with mild COVID-19 who were treated with a combination of nitazoxanide (500 mg q.i.d.), ribavirin, and ivermectin plus zinc supplement compared with 13.7% in those who received supportive symptomatic therapy (no data on statistical significance). 27 In the SARITA-2 study (NCT04552483, n = 392), PCR negativity was achieved in 29.9% of patients who received nitazoxanide (500 mg t.i.d. for 5 days) compared with 18.2% in the placebo arm (p = 0.009) and 55% reduction in viral load compared with 45% (p = 0.013).

However, there was no difference in symptom resolution between the nitazoxanide and the placebo arms. 28 Taken together, all three studies where viral load was evaluated reported some benefit, both studies that evaluated symptom resolution observed no benefit, while both studies that evaluated PCR negativity reported conflicting findings.

Similar to the Vanguard and SARITA-2 studies, this analysis of available data from the NACOVID study showed no difference in clinical improvement or symptom resolution between patients treated with standard of care alone versus standard of care plus nitazoxanide (1000 b.i.d.) and atazanavir/ritonavir. However, we only achieved 64% of the target sample size of 89 required to show or exclude 60% improvement in time to SARS-CoV-2 PCR negativity. 20 Additionally, the limited number of patients with detectable SARS-CoV-2 in saliva at baseline requires that our finding of no difference in viral load change in this trial be interpreted with caution. The choice of saliva for SARS-CoV-2 viral load in this trial was based on observed concordance with nasopharyngeal swabs in the testing laboratory and similar early reports. 29, 30 More recent data now suggest that the suitability of saliva as an alternative to nasopharyngeal swab may be limited to disease stages associated with high viral load. 31, 32 Unfortunately, delays in pre-enrolment testing and diagnosis may have resulted in most patients entering the trial after the exponential phase. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The absence of detectable levels of nitazoxanide active metabolite tizoxanide in saliva samples in this may be indicative of poor penetration into this matrix. If confirmed, this underscores some important points. The use of plasma as a surrogate for target site concentration in COVID-19 should be supported by confirmation of adequate penetration into the respiratory tract and acceptable correlation as with certain antituberculosis drugs. 33 Remdesivir is known to penetrate poorly into human lungs after intravenous administration, 34 and nebulised formulation is currently under development 35 to further enhance its in vivo efficacy. Inhalation delivery with targeted activation within the lungs 36,37 will be an important strategy for drugs with confirmed in vitro activity against SARS-CoV-2 but poor penetration into human lungs.

Reports from other completed nitazoxanide studies are pending while several others are still recruiting, including a phase Ib/IIa study investigating within the AGILE clinical trial platform (NCT04746183) 38 the efficacy of the 1500 mg b.i.d. dosage which was shown to be safe with acceptable tolerability 39 in mild to moderate COVID-19. As it is unlikely that doses higher than 1500 mg b.i.d. will be tolerable, the AGILE trial is expected to provide a firm signal for whether efficacy can be achieved in COVID-19 at any dose.

The protocol for this clinical trial is already published in BMC Trials and subsequent versions with approved amendments are available upon request. All data collection instruments created for this trial have been made available on REDCap as a project template for other users. Requests for data underlying the outcomes reported in this trial to facilitate further analyses in combination with data from other studies will be considered on a case by case basis. Each request should be accompanied by evidence of ethics approval. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint Table 1 . Baseline characteristics of NACOVID trial participants at enrolment. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270152 doi: medRxiv preprint

An interactive web-based dashboard to track COVID-19 in real time

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

WHO Declares COVID-19 a Pandemic

A real-time dashboard of clinical trials for COVID-19

Center for Drug Evaluation and Research. Emergency use authorization (EUA) for molnupiravir

A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs

Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

An Overview of Their Replication and Pathogenesis

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

A minimal common outcome measure set for COVID-19 clinical research

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development

Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group

Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19

Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial

Saliva Is a Promising Alternative Specimen for the Detection of SARS-CoV-2 in Children and Adults

Self-Collected Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2

Diagnostic Performance of Self-Collected Saliva Versus Nasopharyngeal Swab for the Molecular Detection of SARS-CoV-2 in the Clinical Setting

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit

Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro

Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy

Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

The authors appreciate the patients who participated in this trial at the Infectious Disease Hospital, Olodo, Ibadan, and the Olabisi Onabanjo University Teaching Hospital, Sagamu. We thank the staff and management of both hospitals, as well as Oyo and Ogun State government officials who facilitated the conduct of this trial. We thank Dr Kazeem Akano and Mrs Philomena Eromon who conducted

Body weight (kg) 68 (11) 67 (11) 70 (11) 0.322 Body mass index (kg/m 2 ) Underweight (<18. 5